Pilot Study of Bumetanide for Newborn Seizures

Active, not recruiting

Phase 1 Results N/A

Eligibility Criteria

Inclusion Criteria

- newborns with a post-conceptional age of 33-44 weeks
- condition with risk for seizure:
- asphyxia
- intracranial hemorrhage
- suspected or confirmed stroke
- CNS infection
- genetic syndrome
- focal or diffuse brain malformation
- idiopathic or presumed genetic etiology of seizures
- metabolic disorder other than electrolyte disturbances or those caused by renal failure
- suspected clinical seizure

Exclusion Criteria

- have transient metabolic abnormalities (e.g., transient hypocalcemia) as the sole cause of seizures
- are receiving ECMO (extracorporeal membrane oxygenation) therapy because of alteration of bumetanide pharmacokinetics by ECMO
- have contraindications to bumetanide (as determined by treating physician)
- have received diuretics such as furosemide or BTN
- newborns with a total serum bilirubin > 15 mg/dL at enrollment
- newborns given ≥ 40mg/kg of phenobarbital
- loading doses of AEDs other than phenobarbital (those who receive levetiracetam are still eligible since levetiracetam does not affect bumetanide pharmacokinetics)